Rheumatology
Conference Coverage
Latest data: COVID vaccine safety, protection, and breakthrough infections in inflammatory, autoimmune diseases
EULAR 2023 served up a bevy of studies on the protection and safety of COVID vaccines for patients and pregnant and breastfeeding women, as well...
Conference Coverage
Long COVID risk not higher with rheumatic diseases
“The data demonstrate that rheumatic disease itself is not a risk factor for long COVID. However, patients with rheumatic diseases are at a higher...
News
Gout linked to smaller brain volume, higher likelihood of neurodegenerative diseases
Patients with gout may have smaller brains with more iron, and they may be at increased risk for developing dementia and other neurodegenerative...
News
Cell activity in psoriasis may predict disease severity and provide clues to comorbidities
Skin samples from patients with psoriasis showed more fibroblast clusters in the upper layers of the skin in moderate to severe cases.
Conference Coverage
Investigational uricase-based gout drug meets primary endpoints in phase 3 trials
Two phase 3 trials of the once-monthly SEL-212 in refractory gout achieved and maintained serum uric acid < 6 mg/dL for ≥ 80% of the final...
Conference Coverage
URAT1 inhibitor shows ‘substantial’ uric acid reduction in phase 2 gout trial
The investigational drug, AR882, reduced serum uric acid to levels seen in people without hyperuricemia and gout.
News
Cutaneous vasculitis curtails quality of life
Survey respondents described a generally poor health-related quality of life that was detailed as more severe with a skin-specific instrument than...
News
Colchicine’s 2010 price spike had major impact on gout care
Colchicine prescriptions dropped sharply and patient visits for gout-related symptoms increased significantly after a 2010 U.S. Food and Drug...
Conference Coverage
Long-COVID rate may be higher with rheumatic diseases
The results highlight the need for close monitoring and optimized multidisciplinary care for long-term adverse events after COVID-19 in patients...
Conference Coverage
Meta-analysis examines cancer risk concern for JAK inhibitors
Although no increased cancer risk was seen vs. methotrexate or placebo, Janus kinase inhibitors were associated with a higher cancer risk than...